Edwards Lifesciences (NYSE:EW) – Investment analysts at William Blair raised their Q3 2018 earnings estimates for shares of Edwards Lifesciences in a research report issued on Wednesday, April 25th. William Blair analyst M. Kaczor now anticipates that the medical research company will post earnings per share of $1.07 for the quarter, up from their previous estimate of $1.06. William Blair also issued estimates for Edwards Lifesciences’ Q4 2018 earnings at $1.19 EPS, FY2018 earnings at $4.59 EPS, Q1 2019 earnings at $1.23 EPS, Q2 2019 earnings at $1.30 EPS, Q3 2019 earnings at $1.21 EPS, Q4 2019 earnings at $1.34 EPS and FY2019 earnings at $5.07 EPS.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, April 24th. The medical research company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.11. The firm had revenue of $938.00 million for the quarter, compared to analysts’ expectations of $936.69 million. Edwards Lifesciences had a net margin of 17.36% and a return on equity of 28.60%. The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.94 earnings per share.

Other analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $145.00 price objective on the stock in a research note on Thursday, February 8th. Guggenheim reissued a “buy” rating and issued a $162.00 price objective on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Cowen reissued a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, February 1st. SunTrust Banks reissued a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, January 31st. Finally, JMP Securities boosted their price objective on shares of Edwards Lifesciences from $135.00 to $140.00 and gave the stock a “market outperform” rating in a research note on Friday, February 2nd. Five investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $146.51.

NYSE EW opened at $129.29 on Thursday. The firm has a market cap of $27,221.17, a price-to-earnings ratio of 31.77, a P/E/G ratio of 1.87 and a beta of 0.58. Edwards Lifesciences has a fifty-two week low of $100.20 and a fifty-two week high of $143.22. The company has a current ratio of 2.07, a quick ratio of 1.41 and a debt-to-equity ratio of 0.14.

A number of hedge funds have recently added to or reduced their stakes in the stock. Grandeur Peak Global Advisors LLC lifted its holdings in Edwards Lifesciences by 5.4% in the fourth quarter. Grandeur Peak Global Advisors LLC now owns 15,050 shares of the medical research company’s stock valued at $1,696,000 after buying an additional 775 shares during the period. Xact Kapitalforvaltning AB increased its position in shares of Edwards Lifesciences by 21.3% during the fourth quarter. Xact Kapitalforvaltning AB now owns 39,011 shares of the medical research company’s stock worth $4,397,000 after acquiring an additional 6,848 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Edwards Lifesciences by 12.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 199,509 shares of the medical research company’s stock worth $22,485,000 after acquiring an additional 21,929 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its position in shares of Edwards Lifesciences by 11.7% during the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 191,945 shares of the medical research company’s stock worth $21,634,000 after acquiring an additional 20,151 shares in the last quarter. Finally, OLD Mutual Customised Solutions Proprietary Ltd. increased its position in shares of Edwards Lifesciences by 53.4% during the fourth quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 11,198 shares of the medical research company’s stock worth $1,262,000 after acquiring an additional 3,900 shares in the last quarter. Institutional investors and hedge funds own 83.02% of the company’s stock.

In related news, VP Huimin Wang sold 3,800 shares of the business’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $141.84, for a total value of $538,992.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction on Monday, January 29th. The shares were sold at an average price of $127.24, for a total transaction of $674,372.00. Following the completion of the transaction, the vice president now owns 24,908 shares in the company, valued at approximately $3,169,293.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 197,236 shares of company stock worth $26,488,281. 1.84% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Earnings History and Estimates for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.